美股新聞 標題聯播 · 近 24 小時 241 則 · 24 個來源 · 最新 9/20 09:06
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · MBX近 30 天 2 則 · 第 1 / 1 頁
- MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
- MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
- MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
- Stock Market Checklist Helps Uncover Winners In Hot Biotechs
- Attovia Therapeutics Appoints John W. Smither to Board of Directors
- MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
- Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight
- How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?
- MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
- Insider Stock Buying Reaches US$1.06m On MBX Biosciences
- MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。